WINDLAS BIOTECH
|
|
BOM : 543329     NSE : WINDLAS     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : NA |
Dec 12,2024 |
Price(EOD): ₹ 1,058.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 2,211.64 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
WINDLAS BIOTECH | -7.4% | 3.4% | 156.1% |
SUN PHARMACEUTICAL INDUSTRIES | -0% | 0.5% | 46.9% |
CIPLA | -2.1% | -6.9% | 19.3% |
DR REDDYS LABORATORIES | -0.6% | -3.3% | 7.4% |
ZYDUS LIFESCIENCES | -1.9% | 0.7% | 54.5% |
DIVIS LABORATORIES | -3% | 0.9% | 61.2% |
MANKIND PHARMA | 2.5% | 0.2% | 34.3% |
TORRENT PHARMACEUTICALS | -0.1% | 5.6% | 64.3% |
LUPIN | -0.7% | 1.6% | 73.6% |
FUNDAMENTAL ANALYSIS OF WINDLAS BIOTECH
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF WINDLAS BIOTECH
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
36.12
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 61.23 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] 4.97
P/B Calculated based on Book Value of Rs 445.05 Cr
[Latest Year - Mar2024 - Consolidated Results ] 3.18
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 695.65 Cr
[Latest Qtr - Sep2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
1675% 1621% 211% |
SHARE PRICE MOMENTUM OF WINDLAS BIOTECH
WINDLAS BIOTECH vs SENSEX
DEBT OF WINDLAS BIOTECH
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0.02 0.01 |
0 0 0.02 0.01 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF WINDLAS BIOTECH
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF WINDLAS BIOTECH
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
6.76% 10.39% 10.79% 16.17% |
22.49% 23.34% 10.78% 11.6% |
QtrlyTrend |
8 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
WINDLAS BIOTECH related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE SMALL CAP | 0.7% | 4% | 38.4% |
S&P BSE MIDSMALLCAP | 0.7% | 3.9% | 36.9% |
S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
S&P BSE HEALTHCARE | -0.8% | 0.3% | 44.8% |
You may also like the below Video Courses
FAQ about WINDLAS BIOTECH
Is WINDLAS BIOTECH good for long term investment?
As on Dec 12,2024, the Fundamentals of WINDLAS BIOTECH look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of WINDLAS BIOTECH . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is WINDLAS BIOTECH UnderValued or OverValued?
As on Dec 12,2024, WINDLAS BIOTECH is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of WINDLAS BIOTECH ?
As on Dec 12,2024, the Intrinsic Value of WINDLAS BIOTECH is Rs. 61.49 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 59.63
Fair Value [Median EV / Sales Model] : Rs. 61.49
Fair Value [Median Price / Sales Model] : Rs. 340.30
Estimated Median Fair Value of WINDLAS BIOTECH : Rs. 61.49
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.